Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06543849 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients

Study acronym: ITTC
StatusActive, Not Recruiting
PhaseNot applicable
SponsorTang Ziren
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 11, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    v5
  2. Start date: Sep 1, 2024 to Dec 1, 2024v4
  3. Primary endpoints: 3 to 4
    • Secondary endpoints revised (12)
    v3
  4. Primary endpoints: 12 to 3
    • Secondary endpoints: 2 to 12
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tang Ziren
7 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.
Trial Details
NCT Number NCT06543849
Lead Sponsor Tang Ziren
Conditions
(from sponsor)		 Targeted Temperature Management, Cardiac Arrest, Thrombin Function, Treatment Duration
Related terms Heart Arrest
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov